Evidence map›Paper›PMID 38213161›Full record

ArticleCurrent drug targets2024

Molecular Targets and Mechanisms of Hedyotis diffusa Willd. for Esophageal Adenocarcinoma Treatment Based on Network Pharmacology and Weighted Gene Co-expression Network Analysis.

Yu Zhuang, Yun-Gang Sun, Chen-Guang Wang, Qiang Zhang, Chao Che, Feng Shao

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Current computer-aided drug design · 2025
    Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yu ZhuangDepartment of Thoracic Surgery, Nanjing Chest Hospital, Nanjing, Jiangsu, China.ORCID 0000-0001-9171-0769
Yun-Gang SunDepartment of Thoracic Surgery, Nanjing Chest Hospital, Nanjing, Jiangsu, China.
Chen-Guang WangDepartment of Rehabilitation Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Qiang ZhangDepartment of Thoracic Surgery, Nanjing Chest Hospital, Nanjing, Jiangsu, China.
Chao CheE102, Peking University Shenzhen Graduate School, Shenzhen, China.
Feng ShaoDepartment of Thoracic Surgery, Nanjing Chest Hospital, Nanjing, Jiangsu, China.ORCID 0000-0002-6146-0604
Nanjing Brain Hospital · CNNanjing Medical University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHedyotis diffusa Willd. (HDW) is a common anticancer herbal medicine in China, and its therapeutic effectiveness has been demonstrated in a range of cancer patients. There is no consensus about the therapeutic targets and molecular mechanisms of HDW, which contains many active ingredients.

aimTo clarify the mechanism of HDW for esophageal adenocarcinoma (EAC), we utilized network pharmacology and weighted gene co-expression network analysis methods (WGCNA).

methodsThe gene modules that were linked with the clinical features of EAC were obtained through the WGCNA method. Then, the potential target genes were retrieved through the network pharmacology method in order to determine the targets of the active components. After enrichment analysis, a variety of signaling pathways with significant ratios of target genes were found, including regulation of trans-synaptic signaling, neuroactive ligand-receptor interaction and modulation of chemical synaptic transmission. By means of protein-protein interaction (PPI) network analysis, we have successfully identified the hub genes, which were AR, CNR1, GRIK1, MAPK10, MAPT, PGR and PIK3R1.

resultOur study employed molecular docking simulations to evaluate the binding affinity of the active components with the hub gene. The identified active anticancer constituents in HDW are scopoletol, quercetin, ferulic acid, coumarin, and trans-4-methoxycinnamyl alcohol.

conclusionOur findings shed light on the molecular underpinnings of HDW in the treatment of EAC and hold great promise for the identification of potential HDW compounds and biomarkers for EAC therapy.

Indexed as

AdenocarcinomaEsophageal NeoplasmsGene Regulatory NetworksHedyotisMolecular Docking SimulationNetwork PharmacologyAntineoplastic Agents, PhytogenicDrugs, Chinese HerbalGene Expression ProfilingGene Expression Regulation, NeoplasticHumansProtein Interaction MapsSignal TransductionAntineoplastic Agents, PhytogenicDrugs, Chinese HerbalchemotherapyEsophageal adenocarcinomaHedyotis Diffusa Willd. (HDW)network pharmacologyProtein-Protein Interaction (PPI).weighted gene co-expression network analysis

Identifiers

PMID38213161
OpenAlexW4390795452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.